OTCBB:IVBXF

Innovent Biologics Stock News

Healthcare > Biotechnology

Buy IVBXF

*Your capital is at risk

$10.24

-0.190 (-1.83%)

At Close: Jun 03, 2026

Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma

08:00pm, Tuesday, 03'rd Sep 2024

SAN FRANCISCO and SUZHOU, China, Sept. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024

08:13pm, Sunday, 01'st Sep 2024

SAN FRANCISCO and SUZHOU, China , Sept. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024

08:00pm, Wednesday, 28'th Aug 2024

SAN FRANCISCO and SUZHOU, China , Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Innovent Announces 2024 Interim Results and Business Updates

06:37am, Wednesday, 28'th Aug 2024

Strong commercial performance and significant pipeline milestones support sustained growth and innovation SAN FRANSISCO and SUZHOU, China , Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Inno

China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

08:00pm, Wednesday, 21'st Aug 2024

SAN FRANCISCO and SUZHOU, China , Aug. 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial

Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

08:34pm, Thursday, 01'st Aug 2024

SAN FRANSCISO and SUZHOU, China , Aug. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ

Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China

04:40am, Thursday, 01'st Aug 2024

SAN FRANCISCO, U.S. and SUZHOU, China , Aug. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commer

Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development

09:31pm, Thursday, 25'th Jul 2024

SAN FRANCISCO and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ

Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

08:00pm, Sunday, 21'st Jul 2024

SAN FRANCISCO and SUZHOU, China , July 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize

Innovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate Responsibility

08:00pm, Sunday, 07'th Jul 2024

SAN FRANCISCO and SUZHOU, China , July 7, 2024 /PRNewswire/ -- Environmental, Social and Governance (ESG) criteria are key indicators of a company's long-term sustainability. Innovent Biologics has b

Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy

04:30am, Friday, 05'th Jul 2024

SAN FRANCISCO and SUZHOU, China , July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ

Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

08:00pm, Monday, 01'st Jul 2024

SAN FRANCISCO and SUZHOU, China , July 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ

Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline

08:00pm, Thursday, 27'th Jun 2024

SAN FRANCISCO and SUZHOU, China , June 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize

Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

08:14pm, Monday, 24'th Jun 2024

SAN FRANCISCO and SUZHOU, China , June 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize

Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024

08:00pm, Monday, 24'th Jun 2024

SAN FRANCISCO and SUZHOU, China , June 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by